
Sign up to save your podcasts
Or


Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
By Axios4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.

32,130 Listeners

8,749 Listeners

4,182 Listeners

3,958 Listeners

1,512 Listeners

685 Listeners

112,333 Listeners

2,306 Listeners

7,078 Listeners

2,026 Listeners

5,466 Listeners

4,365 Listeners

15,942 Listeners

10,835 Listeners

8,814 Listeners

1,551 Listeners

534 Listeners